Table 3 Patient outcomes, including imaging response, disease relapse, and survival are considered
From: Stereotactic body radiation therapy in the treatment of ovarian cancer
Outcome | Number | Rate |
|---|---|---|
No relapse | 18 | 18% |
Relapse | 80 | 82% |
Two-year local control | Â | 80% |
Local relapse | 17 | 17% |
Regional relapse | 31 | 32% |
Distant relapse | 38 | 39% |
Salvage chemotherapy | 62 | 63% |
Salvage radiotherapy | 35 | 36% |
Salvage surgery | 6 | 6% |
No salvage treatment | 9 | 9% |
Median time to salvage (months) | 4.29 (0.26–51.98) |  |
Alive | 18 | 51% |
Deceased | 17 | 49% |
Median overall survival (months) | 35.19 (1.81–97.64) |  |
Two-year PFS | Â | 12% |
Imaging Response | ||
 Progressive | 1 | 1% |
 Stable | 12 | 12% |
 Partial | 21 | 21% |
 Complete | 52 | 53% |
 No imaging follow-up | 12 | 12% |
Initial median target size (cm) | 2.13 (0.40–15.10) |  |
Target size after SBRT (cm) | 1.50 (0–7.37) |  |
Reduction in target size (%) | 29.17 | Â |
Median neutrophil count reduction | 10.53% | Â |
Median platelet count reduction | 8.57% | Â |
Median lymphocyte count reduction | 14.29% | Â |